SWEAT fluctuated 40.5% in 24 hours: rebounded from a low of $0.0009481 to a high of $0.001332, current price $0.0013317
Bitget Pulse2026/05/23 04:14Volatility Overview
In the past 24 hours, the price of SWEAT rebounded sharply from a low of $0.0009481 to a high of $0.001332, currently stabilizing around $0.0013317, with a range amplitude of 40.5%. After a near-doubling surge from the low, the price has remained at a high level, indicating significant short-term buying activity.
Public market data shows that recent 24-hour trading volumes for SWEAT are in the millions of dollars (reference data for the same period is about $1.6 million), but there is no authoritative real-time disclosure of specific net inflow or outflow data for this cycle.
Brief Analysis of the Cause of the Anomaly
- No official announcements, significant on-chain whale transfers, or specific news events directly triggering this movement were found in the past 24 hours.
- This volatility occurred after a significant surge of +475% to +689% in early May for SWEAT, belonging to a high-volatility continuation phase (previous low around $0.00017062).
- During the same period, exchange developments included previous announcements or implementations by platforms like Bybit and Coins.ph regarding the delisting of SWEAT, which may have some impact on liquidity, but these were not new events within the past 24 hours.
Market Views and Outlook
The community and analysts are divided on the short-term trend of SWEAT: some believe that the previous move-to-earn narrative and the low market cap, high beta attributes maintain speculative appeal; others point out that high volatility brings profit-taking pressure and caution on the risk of a pullback. Mainstream forecasts indicate that short-term prices are easily influenced by overall market liquidity and risk appetite, suggesting attention to on-chain position changes and exchange dynamics.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
